Skip to main content
SpringerLink
Log in

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Primary resistant acute myeloid leukemia (AML) has a very poor prognosis. Etoposide-mitoxantrone-cytarabine (EMA) timed sequential chemotherapy including a first sequence combining mitoxantrone (12 mg/m2 per day over 3 days) with cytarabine (500 mg/m2 per day over the same period), and a second sequence consisting in etoposide (200 mg/m2 per day for 3 days) and cytarabine as in the first sequence, has been proposed as a salvage regimen. Over a 10-year period, 66 primary resistant AML patients have been treated by EMA salvage chemotherapy. All patients displayed intermediate- or high-risk karyotypic abnormalities. Of the 66 patients, 24 [36%, 95% confidence interval (CI): 25–49%] achieved complete remission (CR). Thirty-eight patients were resistant to EMA chemotherapy and four patients died from toxicity during aplasia. After CR achievement, 18 patients received consolidation therapy. Five patients with an HLA-identical sibling donor underwent allogeneic stem cell transplantation (SCT), one patient received autologous SCT, two patients received a second course of EMA chemotherapy, and ten were scheduled for 6-monthly maintenance courses (mini-EMA). Median follow-up was 7.3 years. At the time of analysis, 21 of the 24 patients (87%) who achieved CR have relapsed. Median disease-free survival (DFS) was 5 months (95% CI: 4.3–7.7 months). Median overall survival (OS) was 5 months (95% CI: 3.8–6.7 months). There were only two long-term remitters (3%). In the univariate analysis, CR achievement was mainly related to white blood cell (WBC) count at the time of starting salvage therapy with poorer outcome for patients with more aggressive leukemia (WBC count ≥10×109/l) (CR rates: 50% vs 10%, p<0.001). Overall survival was also influence by WBC count (median OS: 7.2 months vs 2.8 months, respectively, for WBC <and ≥10×109/l, p<0.0001). Initial karyotype was not a significant prognostic factor either for CR achievement or for DFS or OS when comparing patients with normal karyotype and those with chromosomal abnormality. In multivariate analysis, WBC count less than 10×109/l with the absence of circulating blasts at the time of starting salvage therapy appeared to be of favorable prognostic value for CR achievement (p=0.002), while WBC count less than 10×109/l appeared to be of favorable prognostic value for survival (p<0.0001). Using these two objective parameters of proven significance, we devised a prognostic system of immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices. Patients with both factors (WBC count <10×109/l and no circulating blasts) or with at least one at the time of starting salvage therapy had a CR rate of 50% and were therefore candidates for intensified post-remission therapy. All other patients displayed a very poor outcome and must be oriented after failure of first-line therapy to alternate therapeutic programs based on investigational drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide and intermediate dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210–1214

    CAS  Google Scholar 

  2. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D (1991) Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for resistant or relapsing acute myelogenous leukemia. Blood 77:1894–1900

    CAS  PubMed  Google Scholar 

  3. Archimbaud E, Anglaret B, Thomas X, Devaux Y, Ffrench M, Sebban C, Troncy J, Fiere D (1992) Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. Leukemia 6:776–779

    CAS  Google Scholar 

  4. Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyotat D, Fiere D (1994) Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12:262–267

    CAS  PubMed  Google Scholar 

  5. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade Ph, Troncy J, Assouline D, Fière D (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11–18

    CAS  PubMed  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103:626–629

    PubMed  Google Scholar 

  7. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP (1990) High dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473–479

    CAS  Google Scholar 

  8. Burke PJ, Vaughan WP, Karp JE (1980) A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood 55:960–968

    CAS  Google Scholar 

  9. Castaigne S, Archimbaud E, Bordessoule D, Fenaux P, Tilly H, de Revel T, Simon M, Janvier M, Renoux M, Grosbois M, Dupriez B, Zini JM, Tertian G, Legros M, Chastang C, for the AML Study Group (1996) Preliminary results of LAM90 trial on adult acute myelogenous leukemia: comparison of standard induction chemotherapy versus double or sequential induction chemotherapy. Br J Haematol 93 [Suppl 2]:133

  10. Clift R (1987) The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243–258

    CAS  Google Scholar 

  11. Chopra R, Goldstone AH, McMillan AK (1991) Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British Autograft Group experience. J Clin Oncol 9:1840–1847

    CAS  Google Scholar 

  12. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA (1993) The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol 83:404–411

    CAS  PubMed  Google Scholar 

  13. De Witte T, Suciu S, Sellestag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P (1996) Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Ann Hematol 72:119–124

    PubMed  Google Scholar 

  14. De Witte T, Suciu S, Zittoun R, Resegotti L, Liso V, Willemze R, Belhabri A, Amadori S, Giustolisi R, Labar B, Fioritoni G, Rossi-Ferrini G, Leone G, Jehn U, Keating S, Fazi P, Rodts P, Solbu G, Mandelli F (2000) The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC/GIMEMA AML-10 randomized trial (abstract 2167). Blood 96

    Google Scholar 

  15. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Bloom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507–523

    CAS  PubMed  Google Scholar 

  16. Gorin N, Labopin M, Meloni G, Korbling M, Carella A, Hervé P, Burnett A, Rizzoli V, Alessandrino EP, Bjorkstrand B, et al. (1991) Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 5:896–904

    CAS  Google Scholar 

  17. Ho A, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well tolerated regimen. J Clin Oncol 6:213–217

    CAS  PubMed  Google Scholar 

  18. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. (1993) Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 81:1146–1151

    CAS  PubMed  Google Scholar 

  19. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24–30

    CAS  Google Scholar 

  20. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Randomized phase III study AML-9. J Clin Oncol 16:872–881

    PubMed  Google Scholar 

  21. Martinez J, Martin G, Sanz G, Sempere A, Jarque I, de la Rubia J, Sanz MA (1991) A phase II clinical trial of carboplatin infusion in high risk nonlymphoblastic leukemia. J Clin Oncol 9:39–43

    CAS  Google Scholar 

  22. Meloni G, De Fabritiis P, Petti MC, Mandelli F (1990) BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 75:2282–2285

    CAS  Google Scholar 

  23. Preisler HD (1978) Failure of remission induction in acute myelocytic leukemia. Med Ped Oncol 4:275–276

    CAS  Google Scholar 

  24. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Gastaut JA, Laurent G, Molina L, Broustet A, Maraninchi D, Pris J, Hollard D, Faberes C (1996) Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 10:1874–1882

    CAS  Google Scholar 

  25. Santana VM, Mirro JJr, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364–370

    CAS  Google Scholar 

  26. Stanisic S, Kalaycio M (2002) Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2:287–295

    CAS  Google Scholar 

  27. Tavernier E, Le QH, Elhamri M, Thomas X (2003) Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 27:205–214

    CAS  Google Scholar 

  28. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E (1999) Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 13:1214–1220

    Article  CAS  PubMed  Google Scholar 

  29. Vernant JP, Leblond V, Dreyfus F, Colombat P, Pesca A, Troussard X, Allard O, Cordonnier C, Kuentz M, Karianakis G, Bierling P, Rochant H (1986) Results of CHA in adults with acute myeloid leukemia (abstract). IVth International Symposium on Therapy of Acute Leukemias, Rome

  30. World Health Organization (1979) WHO handbook for reporting results of cancer treatment, WHO offset publication 48. WHO, Geneva

Download references

Author information

Authors and Affiliations

  1. Leukemia Unit, Hematology Department, Edouard Herriot Hospital, 69437, Lyon Cedex 03, France

    D. Revesz, Y. Chelghoum, Q. H. Le, M. Michallet & X. Thomas

  2. Biostatistic Department, Lyon Sud Hospital, Pierre-Bénite, France

    Q. H. Le

  3. Clinical Research Unit, Hematology Department, Edouard Herriot Hospital, Lyon, France

    M. Elhamri

Authors
  1. D. Revesz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Chelghoum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q. H. Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Elhamri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Thomas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Revesz, D., Chelghoum, Y., Le, Q.H. et al. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Ann Hematol 82, 684–690 (2003). https://doi.org/10.1007/s00277-003-0730-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0730-1

Keywords

Search

Navigation